Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.77 |
| ▸ | ARG2 | P78540 | 4/20 | 0.48 |
| ▸ | ARG1 | P05089 | 3/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 5/20 | 0.43 |
| ▸ | NOS1 | P29475 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL27588170 | 1.00 | GSR (0.77) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL28046911 | 0.90 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL28331087 | 0.89 | GSR (0.77) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL445453 | 0.88 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL17102268 | 0.88 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL22534312 | 0.88 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL8562830 | 0.88 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL2324976 | 0.88 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL28214073 | 0.88 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL7343 | 0.88 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3617229-B1 | DETECTION REAGENT AND KIT FOR IDENTIFYING ACIDIC STATE AND GLYCATION STATE OF LOW DENSITY LIPOPROTEIN | YAMADA KEN ICHI (JP) | 2024-03-13 | — | — | EP | claimed |
| US-11725002-B2 | Detection reagents and kit for identifying oxidized state and glycated state of low-density lipoproteins | YAMADA, Ken-ichi (JP) | 2023-08-15 | — | — | US | claimed |
| US-20200140426-A1 | DETECTION REAGENTS AND KIT FOR IDENTIFYING OXIDIZED STATE AND GLYCATED STATE OF LOW-DENSITY LIPOPROTEINS | YAMADA, Ken-ichi (JP) | 2020-05-07 | — | — | US | claimed |
| EP-3617229-A1 | DETECTION REAGENT AND KIT FOR IDENTIFYING ACIDIC STATE AND GLYCATION STATE OF LOW DENSITY LIPOPROTEIN | Yamada, Ken-Ichi (JP) | 2020-03-04 | — | — | EP | claimed |
| CN-110799533-A | Detection reagent and kit for identifying acidic state and glycated state of low-density lipoprotein | 扶桑药品工业株式会社 | 2020-02-14 | — | — | CN | claimed |
| US-20050042221-A1 | Compositions and methods for diagnosing Alzheimer's disease | CHOJKIEN MARIO (US) | 2005-02-24 | — | — | US | claimed |
| US-6811988-B2 | AMYLOID PROTEIN FOR USE IN TREATMENT OF NERVOUS SYSTEM DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-02 | — | — | US | claimed |
| EP-1339743-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE | Chojkier, Mario (US) | 2003-09-03 | — | — | EP | claimed |
| US-20030104488-A1 | Compositions and methods for diagnosing Alzheimer's disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-05 | — | — | US | claimed |
| US-20020137112-A1 | Compositions and methods for diagnosing alzheimer's disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-26 | — | — | US | claimed |
| WO-2002046222-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE | CHOJKIER MARIO (US) | 2002-06-13 | — | — | WO | claimed |
| WO-2024117698-A1 | FOOD AND PHARMACEUTICAL COMPOSITION FOR DETOXIFYING ENDOGENOUS ALDEHYDES | PICOENTECH Co., LTD. (KR) | 2024-06-06 | — | — | WO | disclosed |
| US-20240182915-A1 | FOOD AND PHARMACEUTICAL COMPOSITION FOR DETOXIFYING ENDOGENOUS ALDEHYDES | PICOENTECH Co., LTD. (KR) | 2024-06-06 | — | — | US | disclosed |
| US-20240180985-A1 | FOOD AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FATTY LIVER AND INFLAMMATION BY RELIEVING ENDOPLASMIC RETICULUM STRESS | PICOENTECH Co., LTD. (KR) | 2024-06-06 | — | — | US | disclosed |
| WO-2024117697-A1 | FOOD AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FATTY LIVER AND INFLAMMATION BY RELIEVING ENDOPLASMIC RETICULUM STRESS | PICOENTECH Co., LTD. (KR) | 2024-06-06 | — | — | WO | disclosed |
| US-5922757-A | ADMINISTERING ALPHA-TOCOPHEROL TO PATIENTS WITH HEPATITIS C WHO ARE REFRACTORY TO INTERFERON | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1998014181-A1 | TREATMENT AND PREVENTION OF HEPATIC DISORDERS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-09 | — | — | WO | disclosed |
| WO-1997026913-A1 | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0784681-A1 | METHOD OF USING A SCAVENGER RECEPTOR IN THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996011268-A1 | METHOD OF USING A SCAVENGER RECEPTOR IN THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725002-B2 | Detection reagents and kit for identifying oxidized state and glycated state of low-density lipoproteins | APOL1, LDLR, LOX | GSR 356/4885ARG2 1350/4885ARG1 2901/4885 |
| US-20200140426-A1 | DETECTION REAGENTS AND KIT FOR IDENTIFYING OXIDIZED STATE AND GLYCATED STATE OF LOW-DENSITY LIPOPROTEINS | APOL1, LDLR, LOX | GSR 356/4885ARG2 1350/4885ARG1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.